First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS <50% and ≥50% Cohorts of the EVOKE-02 Study
用户EO9nReo4Hj6s
2个月前
76
10
已完结
1. 系统已在2025-12-18 16:47:13对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/j.jtho.2025.10.016
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S1556086425028904
其他信息:
出版社: Elsevier BV
作者: Martin Reck; Jyoti D. Patel; Jhanelle E. Gray; Noemí Reguart; Manuel Cobo; José Fuentes Pradera; Enriqueta Felip; Federico Cappuzzo; Edward B. Garon; Joel W. Neal; Sabeen Mekan; Farnoush Safavi; Nelumka Fernando; Marianna Zavodovskaya; Juliane M. Jürgensmeier; Michael Chisamore; Byoung Chul Cho
